Marc Yaffe announced as ambassador for Cure Leukaemia
Our managing partner, Marc Yaffe, has been made an official ambassador for the national blood cancer charity, Cure Leukaemia.
He recently visited the Royal Manchester Children’s Hospital and met with Professor Rob Wynn and his team, when he learned that four children are diagnosed every day with a form of blood cancer, and is the most common cancer in children and teenagers, affecting children as young as only three months old.
Cure Leukaemia funds Research Nurses as part of the National Trials Acceleration Programme (TAP) Network across 15 cities in the UK. This network enables pioneering blood cancer clinical trials, but the same network does not exist for children who require a stem cell transplant and cell therapy. It is the charity’s goal to reverse this trend by funding a paediatric trials network, designed to deliver practice-changing, world-class, innovative trials with the aim of improving outcomes for children in the UK who are suffering from leukaemia and undergoing a stem cell transplant across major metropolitan cities.
Said Marc: “I’m humbled, and honoured, to be an ambassador for Cure Leukaemia: this is a role I take very seriously. Meeting Professor Wyn and his team has been inspirational, and as the father of three-year-old twins, being in a children’s hospital is an emotional moment for me. It’s my intention to learn as much as I can about Cure Leukaemia, and to use my network to assist in supporting the funding of the proposed paediatric trials network..
James McLaughlin, Cure Leukaemia’s chief executive, said he was delighted to welcome Marc’s support. “When we were first introduced to Marc, we were impressed by his passion and determination to help the charity increase our profile in the North West. The charity has close links to the region through the funding of The Christie and Manchester Royal Infirmary (MRI) hospitals, we are looking forward to working with Marc to help us launch our new paediatric network.”
Left to right Marc Yaffe, JMW managing partner, and Professor Rob Wynn, consultant haematologist, Royal Manchester Children's Hospital.